Vertex Reports First-Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Vertex (VRTX) PT Raised to $125 at Credit Suisse; Raise Probability of Triplet to 75%
April 28, 2017 6:26 AM EDTCredit Suisse raised its price target on Vertex (NASDAQ: VRTX) to $125.00 (from $108.00) while maintaining a Outperform rating.
Analyst Alethia Young raised their probability of success to 75% from 50% to the triplet in the HetMin population. They model $2.1B in peak sales in HetMin.
... MoreVertex Pharma (VRTX) Tops Q1 EPS by 1c
April 27, 2017 4:18 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $481 million versus the consensus estimate of $510.6 million.
"During the quarter, our progress toward treating more people with CF was marked by several important milestones, including expanding the number of people being treated with our approved medicines and developing potential new medicines to treat all people with CF in the future," said Jeffrey Leiden, M.D., Ph.D., Chairman,... More
